NCT05126888尚未招募2 期
A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults With Tourette Syndrome.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 164
- 试验地点
- 4
- 主要终点
- Absolute change from baseline in revised version of Yale Global Tic Severity Scale -Revised - (YGTSS-R-TTS)
研究概览
简要总结
To evaluate the efficacy, safety and tolerability of the cannabinoid-based medication SCI-110 compared to placebo in subjects with Tourette syndrome.
详细描述
It is believed that SCI-110 will be a valuable treatment option, especially for t those subjects with TS, who do not benefit from or do not tolerate first-line treatment with antipsychotics. Since there is evidence that currently available CBM improves not only tics, but also psychiatric comorbidities, SCI-110 might be even more beneficial to improve a broader spectrum of symptoms resulting in both improved quality of life and decreased disease related costs. Moreover, PEA was shown to minimize AEs associated with cannabinoids use and to reduce their required effective dose (data not published). Hence, the use of SCI-110 is expected to show a therapeutic effect superior to currently available CBMs.
It can be assumed that AEs in TS subjects do not differ from AEs described in other groups of subjects treated with medicinal cannabis and/or cannabinoids. In general, cannabinoids are considered as well tolerated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Tourette syndrome according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)
- •Male and female subjects with an age between ≥18 and ≤65 years
- •Total tic score (TTS) of the revised Yale Global Tic Severity Scale (YGTSS-R) >14
- •Clinical Global Impression-Severity Score (CGI-S) ≥4
- •Medication (and stimulation parameters for deep brain stimulation) for tics and comorbidities must be on a stable dose for at least 6 weeks before entering the study and subject must consent to maintain the stable dose during the study
- •Signed written informed consent and willingness to comply with treatment and follow-up procedures
- •Subjects capable of understanding the investigational nature, potential risks and benefits of the clinical study
- •Women of child-bearing potential must have a negative pregnancy test (e.g., urine human chorionic gonadotropin [hCG]) before first treatment with study medication. They must practice a highly effective, reliable and medically approved contraceptive regimen during the study (e.g., theoretical failure rate less than 1% per year as when used consistently and correctly), which include oral or parenteral or implanted hormonal contraception, vaginal ring releasing hormonal contraception (e.g., Nuvaring), intrauterine device or intrauterine system. Women without childbearing potential may enter this study. Women without childbearing potential defined as follows:
- •at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or
- •hysterectomy or uterine agenesis or
- •≥ 50 years and in postmenopausal state ≥ 1 year or
- •< 50 years and in postmenopausal state ≥ 1 year with urine FSH > 40 IU/l and urine oestrogen < 30 ng/l, or serum follicle stimulating hormone (FSH) in the post-menopausal range or a negative oestrogen test.
- •Male subjects must be willing to use a condom with sexual partners during this study and for a period of three months following the last administration of study medication until the follow-up visit. Male subjects must be willing to abstain from sperm donation for 3 months after the completion of this study
排除标准
- •Comorbid obsessive-compulsive disorder (OCD), attention deficit/hyperactivity disorder (ADHD), depression, and anxiety disorder when unstable or in need of an initial adjustment for a therapy-according to the investigator's judgment
- •Presence of severe psychiatric conditions such as developmental disability, psychotic illness and bipolar disorder- according to the investigator's judgment
- •Ongoing behavioural treatment for tics
- •History of schizophrenia, seizure, psychotic, severe personality, or pervasive developmental disorder
- •Current clinical diagnosis of substance abuse or dependence
- •History of cannabis dependence
- •Secondary and other chronic tic disorders or other significant neurological disorders
- •Known severe cardiac diseases, known severe cardiovascular diseases, known positivity for human immunodeficiency virus (HIV), hepatitis C, hepatitis B, or other severe hepatic and renal disorders by history
- •Concomitant medications have to be on stable dose since at least 6 weeks before entering the study and must be well tolerated at baseline without causing dizziness, confusion, sedation, or somnolence)
- •Use of cannabis or cannabinoid-based medicine (CBM) in the 30-day period prior to study entry and/or positive delta-9-tetrahydrocannabinol (THC) urine test at baseline
- •Positive urine ß-HCG pregnancy test
- •Pregnant or breast-feeding women
- •Subjects who received any investigational medication or used any investigational device within 30 days prior to the first dose of study medication or is actively participating in any investigational drug or device study, or is scheduled to receive an investigational drug or to use an investigational device during the course of the study
- •Subjects with a known allergy, hypersensitivity, or intolerance to the active substances and ingredients of study medication (e.g., cannabis, cannabinoids, or sesame oil)
- •Any condition, which in the opinion of the investigator, would interfere with the evaluation of the study product or poses a health risk to the subject
- •Subjects who are employees of the sponsor or employees or close relatives of the investigator
- •Subjects with active suicidal ideation and behaviour (SI/B) according to the Columbia-Suicide Severity Rating Scale (C-SSRS) and/or subjects that have attempted suicide in the past.
研究组 & 干预措施
Dronabinol
Placebo Comparator
Placebo matched in taste, odour and appearance to SCI-110
干预措施: Placebo (Other)
SCI-110
Experimental
Cannabinoid-based medication consisting of Dronabinol and PEA
干预措施: SCI-110 (Drug)
结局指标
主要结局
Absolute change from baseline in revised version of Yale Global Tic Severity Scale -Revised - (YGTSS-R-TTS)
时间窗: At baseline and 12 weeks after start of treatment in both arms.
Absolute change from baseline in revised version of YGTSS-R-TTS as a continuous endpoint at week 12 of the respective treatment period. The Global Severity Score has a range of 0- 100. A higher score on the scale suggests a more severe Tic, or a greater impact the Tic has on the person's life.
[CCI]
[CCI]
次要结局
- Percent reduction in Yale Global Tic Severity Scale -Revised - (YGTSS-R-TTS) of at least 20%(At baseline and 12 weeks after start of treatment in both arms.)
- Percent reduction in Yale Global Tic Severity Scale -Revised - (YGTSS-R-TTS) of at least 30%, 35% and 50%(Week 12 of each treatment period (visit 8 and 15).)
- Absolute change from baseline of YGTSS-R Total Score(At baseline and 12 weeks after start of treatment in both arms.)
- Percent change from baseline of YGTSS-R Total Score(At baseline and 12 weeks after start of treatment in both arms.)
- Clinical Global Impression-Improvement Score (CGI-I)(24 weeks)
- Clinical Global Impression-Severity Score (CGI-S) Absolute result(24 weeks)
- Clinical Global Impression-Severity Score (CGI-S) Percent result(24 weeks)
- Total Pre-monitory Urge for Tics Scale (PUTS) Absolute Score(24 weeks)
- Total Pre-monitory Urge for Tics Scale (PUTS) Percent Score(24 weeks)
- Adult Tic Questionnaire (ATQ) Percent Score(24 weeks)
- Adult Tic Questionnaire (ATQ) Absolute Score(24 weeks)
- Changes in Beck Depression Inventory (BDI-II) Percent score.(24 weeks)
- Changes in Beck Depression Inventory (BDI-II) absolute score.(24 weeks)
- Changes in Yale-Brown Obsessive Compulsive Scale (Y BOCS) absolute score(24 weeks)
- Changes in Yale-Brown Obsessive Compulsive Scale (Y BOCS) Percent score(24 weeks)
- Changes in Obsessive-compulsive disorder (OCD) severity Absolute score(24 weeks)
- Changes in Obsessive-compulsive disorder (OCD) severity Percent score(24 weeks)
- Changes in Conners' Adult ADHD Rating Scale (CAARS) Absolute score.(24 weeks)
- Changes in Conners' Adult ADHD Rating Scale (CAARS) Percent score(24 weeks)
- Changes in Beck Anxiety Inventory (BAI) Absolute scores(24 weeks)
- Changes in Beck Anxiety Inventory (BAI) percent scores(24 weeks)
- Changes in Beck Depression Inventory (BDI) Absolute score(24 weeks)
- Changes in Beck Depression Inventory (BDI) percent score(24 weeks)
- Changes in Rage Attacks Questionnaire (RAQ-R) Absolute scores(24 weeks)
- Changes in Rage Attacks Questionnaire (RAQ-R) percent scores(24 weeks)
- Changes in Pittsburgh Sleep Quality Index (PSQI) Absolute scores(24 weeks)
- Changes in Pittsburgh Sleep Quality Index (PSQI) Percent scores(24 weeks)
- Changes to the Tourette Syndrome-Quality of Life Scale (GTS-QoL) score(24 weeks)
- Changes to the 12-item short-form Health Survey (SF-12) score(24 weeks)
- [CCI]
- Number of adverse events (AEs), number and rate of patients affected by AEs, SAEs, SUSARs/ADRs, AESIs and AEs leading to withdrawal at each visit.
- Absolute values of vital signs (blood pressure, heart rate) at each visit and change from baseline for each visit. Number and percentage of clinically significant abnormal values.
研究者
Clinical trial information
Scientific
Scisparc Ltd.
研究点 (4)
Loading locations...
相似试验
招募中
4 期
Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine AddictsCocaine DependenceNCT06159387University of Sao Paulo General Hospital60
终止
3 期
A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile SpasmsInfantile SpasmNCT03421496Radius Pharmaceuticals, Inc.2
已完成
1 期
A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's DiseaseParkinson's DiseaseNCT00866502Newron Sweden AB12
已完成
1 期
Cannabinol Use in Patients With Insomnia DisorderInsomnia DisorderNCT05344170Woolcock Institute of Medical Research20
尚未招募
1 期
Phase 1a Study in Healthy ParticipantsHealthyNCT05953506Jiangsu Hansoh Pharmaceutical Co., Ltd.52